JPRN-jRCT2080225288招募中1 期
Phase I study of CBA-1205
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •ECOG performance status: <= 1
- •- Patients with 3 months or longer life expectancy
排除标准
- •- Patients who received other investigational drug or immune checkpoint inhibitor within 28 days prior to enrollment
- •- Patients who received anti-cancer drug within 14 days prior to enrollment
研究者
相似试验
招募中
1 期
Phase I study of CBA-1535JPRN-jRCT2031210708Tanaka Miseri70
进行中（未招募）
1 期
Phase Ib / II study of BAY 1000394 in combination with cisplatin / etoposide or carboplatin / etoposide as first-line therapy in subjects with extensive disease small cell lung cancerSubjects with histologically or cytologically confirmed, extensive disease SCLC without prior systemic antitumor therapy are eligible. Subjects should have evaluable or measurable disease.MedDRA version: 14.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004155-39-FRBayer Healthcare AG60
进行中（未招募）
1 期
A Phase II uncontrolled study of BAY 73-4506 in previously untreated patients with metastatic or unresectable renal cell cancer (RCC)Renal Cell CarcinomaMedDRA version: 20.0Level: LLTClassification code 10038407Term: Renal cell cancerSystem Organ Class: 100000004864EUCTR2008-000107-28-GBBayer HealthCare Pharmaceuticals Inc49
进行中（未招募）
不适用
Phase II Studie zur Evaluierung der SH U 555 C unterstützten Magnetresonanztomographie der arteriosklerotischen Karotisstenose bei Patienten vor ThrombendarteriektomieArteriosklerotische KarotisstenoseEUCTR2005-001415-21-DEInstitut für Röntgendiagnostik der Technischen Universität München20
进行中（未招募）
不适用
Protocol CA180015: A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib MesylateEUCTR2004-002517-36-ITBRISTOL-M.SQUIBB